Article

Cotransplantation of haploidentical hematopoietic and umbilical cord mesenchymal stem cells for severe aplastic anemia: Successful engraftment and mild GVHD

Department of Hematology, The First Affiliated Hospital, Chinese PLA General Hospital, Beijing 100048, China.
Stem Cell Research (Impact Factor: 3.91). 10/2013; 12(1):132-138. DOI: 10.1016/j.scr.2013.10.001
Source: PubMed

ABSTRACT Haploidentical hematopoietic stem-cell transplantation (haplo-HSCT) is associated with an increased risk of graft failure and severe graft-versus-host disease (GVHD). Mesenchymal stromal cells (MSCs) have been shown to support in vivo normal hematopoiesis and to display potent immunesuppressive effects. We cotransplanted the culture-expanded third-party donor-derived umbilical cord MSCs (UC-MSCs) in 21 young people with severe aplastic anemia (SAA) undergoing haplo-HSCT without T-cell-depleted. We observed that all patients had sustained hematopoietic engraftment without any adverse UC-MSC infusion-related events. Furthermore, we did not observe any increase in severe aGVHD. These data suggest that UC-MSCs, possibly thanks to their potent immunosuppressive effect on allo-reactive host T lymphocytes escaping the preparative regimen, reduce the risk of graft failure and severe GVHD in haplo-HSCT.

0 Followers
 · 
49 Views
 · 
0 Downloads
  • [Show abstract] [Hide abstract]
    ABSTRACT: The immune response to infection is a rapid and multifaceted process. Infection affects homeostasis within the hematopoietic stem cell (HSC) niche, as lost immune cells must be replaced by HSCs. During the immune response, interferon is produced. Surprisingly, HSCs respond directly to interferon, entering the cell cycle from even the most dormant state. The complex response of both the HSCs and the niche to infection is a unique platform on which to consider HSC–niche interactions. Here, we comment on the contribution of the immune system to the niche and on the direct and indirect effect that infection has on HSCs in the niche.
    Annals of the New York Academy of Sciences 03/2014; 1310(1). DOI:10.1111/nyas.12400 · 4.31 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: To evaluate the efficacy and safety of cotransplantation of human umbilical cord mesenchymal stem cells (UC-MSCs) and haploidentical hematopoietic stem cells (HSCs) and to determine the correlation factors affecting incidence of graft versus host disease (GVHD) in patients with severe aplastic anemia (SAA), twenty-four SAA patients received haploidentical HSCs and UC-MSCs co-transplantation. Grafts came from a combination of granulocyte colony stimulating factor (G-CSF)-primed bone marrow and G-CSF mobilized peripheral blood stem cell of haploidentical donors, and in vitro expanded third-party donor derived UC-MSCs were employed as the cell graft. The conditioning regimens consisted of rabbit anti-human T-lymphocyte immunoglobulin (ATG), cyclophosphamide and fludarabine with or without busulfan. GVHD was prevented by using cyclosporine A (CSA), ATG, anti-CD25 monoclonal antibody and mycophenolate mofetil. All 24 patients achieved hematopoietic reconstitution. Median time to absolute neutrophil count >2 × 10(9)/L and platelet count >20 × 10(9)/L were 11 and 13 days, respectively. An incidence of 25 % on grade I-II acute GVHD was found while an incidence of 25 % of grade III-IV acute GVHD was seen. Blood type (r = 0.152, P = 0.043) and patient/donor pair (r = 0.541, P = 0.022) were significantly correlated with incidence of cGVHD. Transplantation related mortality was observed in 20.8 % of the cases. Co-transplantation of haploidentical HSCs and hUC-MSCs on SAA was an effective and safe approach in reducing GVHD and transplantation related mortality. The adequate conditioning regimen and early treatment for infection also played a critical role in the success of HSCT.
    Cytotechnology 11/2014; DOI:10.1007/s10616-014-9793-1 · 1.45 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Since the 1960s and the therapeutic use of hematopoietic stem cells of bone marrow origin, there has been an increasing interest in the study of undifferentiated progenitors that have the ability to proliferate and differentiate into various tissues. Stem cells (SC) with different potency can be isolated and characterised. Despite the promise of embryonic stem cells, in many cases, adult or even fetal stem cells provide a more interesting approach for clinical applications. It is undeniable that mesenchymal stem cells (MSC) from bone marrow, adipose tissue, or Wharton’s Jelly are of potential interest for clinical applications in regenerative medicine because they are easily available without ethical problems for their uses. During the last 10 years, these multipotent cells have generated considerable interest and have particularly been shown to escape to allogeneic immune response and be capable of immunomodulatory activity. These properties may be of a great interest for regenerative medicine. Different clinical applications are under study (cardiac insufficiency, atherosclerosis, stroke, bone and cartilage deterioration, diabetes, urology, liver, ophthalmology, and organ’s reconstruction). This review focuses mainly on tissue and organ regeneration using SC and in particular MSC.
    Stem cell International 01/2015; 2015(11):1-19. DOI:10.1155/2015/734731 · 2.81 Impact Factor
Show more

Preview

Download
0 Downloads
Available from